GLO1 and neoplasm: Similarly, GLO1 inhibitors have been shown to limit tumor progression and increase the sensitivity of conventional anticancer therapeutic agents in colorectal cancer (134, 161), melanoma, hepatocellular carcinoma (147, 162), and gastric cancer (163).